We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

63 hedge funds and large institutions have $160M invested in Syndax Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 3

100% more capital invested

Capital invested by funds: $79.8M → $160M (+$80.1M)

73% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 11

11% more funds holding

Funds holding: 57 → 63 (+6)

2.73% more ownership

Funds ownership: 61.15% → 63.89% (+2.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
63
Holders Change
+6
Holders Change %
+10.53%
% of All Funds
1.57%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
19
Reduced
11
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$14.8M
2
HIM
Hillhouse Investment Management
Cayman Islands
+$2.55M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$2.48M
4
AG
Artal Group
Luxembourg
+$2.08M
5
Millennium Management
Millennium Management
New York
+$2.05M

Top Sellers

1
O
OrbiMed
New York
-$2.83M
2
EC
EcoR1 Capital
California
-$2.48M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.39M
4
Jennison Associates
Jennison Associates
New York
-$672K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$546K
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
51
STRS Ohio
Ohio
$20K – – –
UBS Group
52
UBS Group
Switzerland
$20K +$6.91K +665 +82%
CSS
53
Cubist Systematic Strategies
Connecticut
$16K -$15.2K -1,466 -55%
FPFS
54
First Personal Financial Services
North Carolina
$15K – – –
Legal & General Group
55
Legal & General Group
United Kingdom
$15K – – –
Bank of America
56
Bank of America
North Carolina
$11K +$1.94K +187 +29%
AIP
57
Ameritas Investment Partners
Nebraska
$5K +$3.81K +367 New
IUHSA
58
Itau Unibanco Holding S.A.
Brazil
$4K +$2.71K +261 New
Royal Bank of Canada
59
Royal Bank of Canada
Ontario, Canada
$3K -$374 -36 -13%
MAM
60
Meeder Asset Management
Ohio
$3K +$62 +6 +3%
Citigroup
61
Citigroup
New York
$2K +$1.27K +122 +3,050%
Manulife (Manufacturers Life Insurance)
62
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K – – –
BNP Paribas Financial Markets
63
BNP Paribas Financial Markets
France
$123 -$582 -56 -86%
Jennison Associates
64
Jennison Associates
New York
– -$672K -93,783 Closed
TC
65
TFS Capital
Pennsylvania
– -$116K -16,130 Closed
TRCT
66
Tower Research Capital (TRC)
New York
– -$26K -3,547 Closed
1 2
3

SNDX Hedge Fund Activity: Q1 2017 in Review

63 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2017, worth a combined $160M — up 100% from $79.8M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new SNDX positions and 3 closed out — a net gain of 12 holders — while 19 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $14.8M. The largest seller was OrbiMed, cutting an estimated $2.83M.

  • 63 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2017, up from 57 in Q4 2016.
  • Funds reported $160M of Syndax Pharmaceuticals stock for Q1 2017, up 100% quarter-over-quarter.
  • 15 funds opened new Syndax Pharmaceuticals positions in Q1 2017 and 3 closed out, a net change of +12 holders.
  • The largest Syndax Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $14.8M added.
  • The largest Syndax Pharmaceuticals seller in Q1 2017 was OrbiMed, an estimated $2.83M sold.

Based on aggregated 13F filings for Q1 2017.